The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | REVEAL: association between elevated blood counts and thrombotic events in polycythemia vera
Aaron Gerds, MD, MS, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, comments on the results of REVEAL, a real-world prospective observational study investigating the association between white blood cell and platelet counts and the risk of thrombosis in patients with polycythemia vera (PV). While the study found a significant association between elevated white blood cell counts and an increased risk of thrombosis, platelet counts were only associated with a higher risk of thrombosis below a specific threshold. This data could help refine the current risk prognostication system for thrombosis in patients with PV. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Consulting or Advisory Role – Abbvie; Bristol-Myers Squibb; Constellation Pharmaceuticals; CTI BioPharma Corp; Novartis; PharmaEssentia; Sierra Oncology
